2012 UALC
David Barbie, MD
Dana-Farber Cancer Institute
Research Project:
Evaluation of a Novel Immune Kinase Inhibitor for KRAS-Driven Lung Cancer
Summary:
Dr. Barbie’s research is focused on improving treatment for a subset of non-small cell lung cancer patients with tumors harboring activating Kras mutations, representing approximately 30% of with no currently available targeted therapy. Dr. Barbie will be investigating a new drug (CYT-387) targeting a signaling pathway commonly activated in immune cells, but also triggered by Kras activating mutations found in lung tumors. This project will characterize the drug’s mechanism of action and therapeutic potential in order to develop new strategies for combination therapy for lung cancer patients.